143 related articles for article (PubMed ID: 11483401)
41. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.
Koga M; Gilbert M; Li J; Koike S; Takahashi M; Furukawa K; Hirata K; Yuki N
Neurology; 2005 May; 64(9):1605-11. PubMed ID: 15883324
[TBL] [Abstract][Full Text] [Related]
42. Serologic evidence of Campylobacter jejuni/coli enteritis in patients with Guillain-Barré syndrome.
Gruenewald R; Ropper AH; Lior H; Chan J; Lee R; Molinaro VS
Arch Neurol; 1991 Oct; 48(10):1080-2. PubMed ID: 1929902
[TBL] [Abstract][Full Text] [Related]
43. Guillain-Barré syndrome and Fisher's syndrome following Campylobacter jejuni infection.
Yuki N; Miyatake T
Ann N Y Acad Sci; 1998 Jun; 845():330-40. PubMed ID: 9668366
[TBL] [Abstract][Full Text] [Related]
44. Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome.
Neisser A; Bernheimer H; Berger T; Moran AP; Schwerer B
Infect Immun; 1997 Oct; 65(10):4038-42. PubMed ID: 9317004
[TBL] [Abstract][Full Text] [Related]
45. Successive yet distinct episodes of isolated ophthalmoplegia associated with anti-GQ1b antibody.
Cardenas D; Mishra SK; Ohanian AG; Ovbiagele B
Neurology; 2005 Jul; 65(1):163. PubMed ID: 16009911
[No Abstract] [Full Text] [Related]
46. [A case of Guillain-Barré syndrome after the travel in southeast Asia--isolation of Campylobacter jejuni PEN 5 serotype].
Koide T; Yamazaki M; Onishi Y; Saito K; Yuki N
Rinsho Shinkeigaku; 1997 Jan; 37(1):41-3. PubMed ID: 9146072
[TBL] [Abstract][Full Text] [Related]
47. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues.
Kuroki S; Saida T; Nukina M; Haruta T; Yoshioka M; Kobayashi Y; Nakanishi H
Ann Neurol; 1993 Mar; 33(3):243-7. PubMed ID: 8498807
[TBL] [Abstract][Full Text] [Related]
48. Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects.
Tribble DR; Baqar S; Carmolli MP; Porter C; Pierce KK; Sadigh K; Guerry P; Larsson CJ; Rockabrand D; Ventone CH; Poly F; Lyon CE; Dakdouk S; Fingar A; Gilliland T; Daunais P; Jones E; Rymarchyk S; Huston C; Darsley M; Kirkpatrick BD
Clin Infect Dis; 2009 Nov; 49(10):1512-9. PubMed ID: 19842970
[TBL] [Abstract][Full Text] [Related]
49. Campylobacter jejuni and Guillain-Barré syndrome.
Rees JH; Hughes RA
Ann Neurol; 1994 Feb; 35(2):248-9. PubMed ID: 8109911
[No Abstract] [Full Text] [Related]
50. Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients.
Strid MA; Engberg J; Larsen LB; Begtrup K; Mølbak K; Krogfelt KA
Clin Diagn Lab Immunol; 2001 Mar; 8(2):314-9. PubMed ID: 11238214
[TBL] [Abstract][Full Text] [Related]
51. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh.
Islam Z; Jacobs BC; van Belkum A; Mohammad QD; Islam MB; Herbrink P; Diorditsa S; Luby SP; Talukder KA; Endtz HP
Neurology; 2010 Feb; 74(7):581-7. PubMed ID: 20157160
[TBL] [Abstract][Full Text] [Related]
52. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
Jacobs BC; Hazenberg MP; van Doorn PA; Endtz HP; van der Meché FG
J Infect Dis; 1997 Mar; 175(3):729-33. PubMed ID: 9041356
[TBL] [Abstract][Full Text] [Related]
53. Bacterial infections in Guillain-Barré and Fisher syndromes.
Yuki N; Koga M
Curr Opin Neurol; 2006 Oct; 19(5):451-7. PubMed ID: 16969154
[TBL] [Abstract][Full Text] [Related]
54. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies.
Kimoto K; Koga M; Odaka M; Hirata K; Takahashi M; Li J; Gilbert M; Yuki N
Neurology; 2006 Nov; 67(10):1837-43. PubMed ID: 17130419
[TBL] [Abstract][Full Text] [Related]
55. Microbiologic approaches for studying Campylobacter species in patients with Guillain-Barré syndrome.
Nachamkin I
J Infect Dis; 1997 Dec; 176 Suppl 2():S106-14. PubMed ID: 9396692
[TBL] [Abstract][Full Text] [Related]
56. Relationship between pathogenesis of Guillain-Barre syndrome and Penner's serotypes of Campylobacter jejuni.
Li H; Yuan J; Shen B; Sun X; Hao H
Chin Med J (Engl); 1999 Sep; 112(9):794-6. PubMed ID: 11717947
[TBL] [Abstract][Full Text] [Related]
57. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.
Jacobs BC; van Doorn PA; Schmitz PI; Tio-Gillen AP; Herbrink P; Visser LH; Hooijkass H; van der Meché FG
Ann Neurol; 1996 Aug; 40(2):181-7. PubMed ID: 8773599
[TBL] [Abstract][Full Text] [Related]
58. Benign intracranial hypertension: atypical presentation of Miller Fisher syndrome?
Mewasingh LD; Sékhara T; Dachy B; Djeunang MC; Dan B
Pediatr Neurol; 2002 Mar; 26(3):228-30. PubMed ID: 11955933
[TBL] [Abstract][Full Text] [Related]
59. Detection of antibodies against Campylobacter jejuni serogroup PEN O:19 purified flagellar protein in a patient with Guillain-Barré syndrome.
Lange D; Aleksic S; Kassubek J; Vrvic MM; Kist M; Steinbrückner B; Mitova M
Zentralbl Bakteriol; 1999 Oct; 289(4):429-44. PubMed ID: 10603661
[TBL] [Abstract][Full Text] [Related]
60. Are Campylobacter curvus and Campylobacter upsaliensis antecedent infectious agents in Guillain-Barré and Fisher's syndromes?
Koga M; Yuki N; Takahashi M; Saito K; Hirata K
J Neurol Sci; 1999 Feb; 163(1):53-7. PubMed ID: 10223411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
